|
Contact your Area Business Specialist
[First, Last - ABS@strongbridgebio.com]
to schedule a peer-to-peer discussion
with an expert.
|
|
|
References:
1. Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57:522-530.
2. Charles G, Zheng C, Lehmann-Horn F, Jurkatt-Rott K, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613.
3. Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126-133.
|
|
This message was sent by: Strongbridge Biopharma • 900 Northbrook Drive, Suite 200 • Trevose, PA 19053
|
|
This message and any attachments are for the designated recipient only and may contain privileged, proprietary, or otherwise private information. If you have received this in error, please notify the sender immediately and delete this message. Any other use of this email is prohibited.
|
|
Unsubscribe from this list.
|
|
|
www.strongbridgebio.com
|
|
© 2018 Strongbridge Biopharma plc
|
|
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
|
|
KEV-0396 07/2018
|